SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$1.9B
Q2 2024
Positions
61
Filings on Record
27
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Boxer Capital, LLC reported $1.9B in U.S.-listed holdings across 61 positions for Q2 2024.

Its largest position, RVMD, represents 8.7% of the portfolio.

Compared with Q1 2024, the fund opened 4 new positions and exited 2.

Portfolio Metrics

Turnover
+10.9%
vs prior filed quarter
Top-10 Concentration
+54.3%
share of reported value
Largest Position
+8.7%
Revolution Medicines
New / Exited
4 / 2
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 83.3%Other: 8.4%ADR: 8.2%Equity WRT: 0.0%
  • Common Stock · 83.3% · $1.6B
  • Other · 8.4% · $160M
  • ADR · 8.2% · $157M
  • Equity WRT · 0.0% · $43,774

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CLYMEliem Therapeutics IncNEW+2.60M2.60M+$19M$19M
REPLReplimune Group IncNEW+1.54M1.54M+$14M$14M
CGEMCullinan Therapeutics IncNEW+657.9K657.9K+$11M$11M
OLMAOlema Pharmaceuticals IncNEW+650.0K650.0K+$7M$7M
TARAProtara Therapeutics IncADDED+602.4K811.6K+$849,184$2M
IPSCCentury Therapeutics IncADDED+3.15M4.90M+$5M$12M
SYRESpyre Therapeutics IncADDED+446.5K696.5K+$7M$16M
VKTXViking Therapeutics IncSOLD OUT−300.0K0−$25M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RVMDRevolution Medicines Inchistory →COM8.75%$166M4.28M
2SWTXUSDSpringworks Therapeutics Inchistory →COM6.79%$129M3.42M
3CYTKCytokinetics Inchistory →COM NEW5.99%$114M2.10M
4Merus N VCOM5.92%$112M1.90M
5TYRATyra Biosciences Inchistory →COM5.43%$103M6.45M
6SRPTSarepta Therapeutics Inchistory →COM5.41%$103M650.0K
7NUVLNuvalent Inchistory →COM4.48%$85M1.12M
8IDYAIdeaya Biosciences Inchistory →COM4.07%$77M2.20M
9ONCBeiGene Ltdhistory →SPONSORED ADR3.76%$71M500.0K
10RNAGBPAvidity Biosciences Inchistory →COM3.72%$71M1.73M
11TNGXTango Therapeutics Inchistory →COM3.70%$70M8.20M
12APLSUSDApellis Pharmaceuticals Inchistory →COM3.49%$66M1.73M
132662247DiTeos Therapeutics Inchistory →COM2.30%$44M2.95M
14ARGXArgenx SEhistory →SPONSORED ADR2.26%$43M100.0K
15AKROAkero Therapeutics Inchistory →COM2.07%$39M1.68M
16NKTXNkarta Inchistory →COM1.75%$33M5.61M
17ANABAnaptysBio Inchistory →COM1.72%$33M1.30M
18AXSMAxsome Therapeutics Inchistory →COM1.70%$32M400.0K
19RCKTRocket Pharmaceuticals Inchistory →COM1.66%$32M1.47M
20FATEFate Therapeutics Inchistory →COM1.42%$27M8.22M
21LEGNLegend Biotech Corphistory →SPONSORED ADS1.40%$27M600.0K
22Third Harmonic Bio IncCOM1.37%$26M2.00M
23GONGeron Corphistory →COM1.34%$25M6.00M
24RCUSArcus Biosciences Inchistory →COM1.29%$24M1.60M
25XENEXenon Pharmaceuticals Inchistory →COM1.23%$23M600.0K
26IMVTImmunovant Inchistory →COM1.15%$22M825.0K
27KURAKura Oncology Inchistory →COM1.08%$21M1.00M
284XC1Kalvista Pharmaceuticals Inchistory →COM0.99%$19M1.59M
29CLYMEliem Therapeutics Inchistory →COM0.97%$19M2.60M
30DAWNGBXDay One Biopharmaceuticals Ihistory →COM0.86%$16M1.19M
31SYRESpyre Therapeutics Inchistory →COM NEW0.86%$16M696.5K
32ARVNArvinas Inchistory →COM0.85%$16M608.6K
33GPCRStructure Therapeutics Inchistory →SPONSORED ADS0.83%$16M400.0K
34ELVNEnliven Therapeutics Inchistory →COM0.83%$16M671.4K
35Prothena Corp PLCSHS0.75%$14M690.0K
36REPLReplimune Group Inchistory →COM0.73%$14M1.54M
37PSTXUSDPoseida Therapeuticshistory →COM0.69%$13M4.47M
38IPSCCentury Therapeutics Inchistory →COM0.66%$12M4.90M
39ORICOric Pharmaceuticals Inchistory →COM0.65%$12M1.73M
40RLAYRelay Therapeutics Inchistory →COM0.62%$12M1.82M
41CGEMCullinan Therapeutics Inchistory →COM0.60%$11M657.9K
42PRLDPrelude Therapeutics IncCOM0.52%$10M2.57M
43ALLOAllogene Therapeutics IncCOM0.47%$9M3.85M
44SANASana Biotechnology IncCOM0.44%$8M1.54M
45JSPRJasper Therapeutics IncCOM NEW0.42%$8M350.0K
46OLMAOlema Pharmaceuticals IncCOM0.37%$7M650.0K
47Engene Holdings IncCOM0.36%$7M727.9K
48IOVAIovance Biotherapeutics IncCOM0.32%$6M750.0K
49AMLXAmylyx Pharmaceuticals IncCOM0.15%$3M1.50M
50BOLDBoundless Bio IncCOM0.14%$3M711.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.